Functional assessment of the acute local and distal transplantation of human neural stem cells after spinal cord injury

Cheng, Ivan; Mayle, R. E.; Cox, Christopher A.; Park, Don Y.; Smith, Robert L.; Corcoran-Schwartz, Ian; Ponnusamy, Karthikeyan; Oshtory, Rayshad; Smuck, Matthew; Mitra, Raj; Kharazi, Alexander I.; Carragee, Eugene J.

doi:10.1016/j.spinee.2012.09.005

Cited by 26 publications

(20 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These cells proved to be capable of long-term expansion when cultured in mitogens such as epidermal growth factor (EGF) and fibroblast growth factor-2 (FGF-2), even without genetic modification, while maintaining their neurogenic and gliogenic multipotent differentiation potential. Fetal-NSCs have shown therapeutic potential for a number of neurological diseases such as stroke (Kalladka et al, 2016;Pollock et al, 2006), traumatic brain injury (Shin et al, 2015;Skardelly et al, 2011), spinal cord injury (Cheng et al, 2012;Shin et al, 2015), and amyotrophic lateral sclerosis (Glass et al, 2012;Xu et al, 2006). However, previous studies have shown that fetal-NSCs undergo senescence earlier than other NSC lines, which would make large-scale manufacturing more difficult (Wright, Prowse, Wallace, Linskens, & Svendsen, 2006).…”

Section: Fetal-derived Neural Stem Cellsmentioning

confidence: 99%

Neural stem cell therapy for stroke: A multimechanistic approach to restoring neurological function

2019

View full text Add to dashboard Cite

Introduction Neural stem cells (NSCs) have demonstrated multimodal therapeutic function for stroke, which is the leading cause of long‐term disability and the second leading cause of death worldwide. In preclinical stroke models, NSCs have been shown to modulate inflammation, foster neuroplasticity and neural reorganization, promote angiogenesis, and act as a cellular replacement by differentiating into mature neural cell types. However, there are several key technical questions to address before NSC therapy can be applied to the clinical setting on a large scale. Purpose of Review In this review, we will discuss the various sources of NSCs, their therapeutic modes of action to enhance stroke recovery, and considerations for the clinical translation of NSC therapies. Understanding the key factors involved in NSC‐mediated tissue recovery and addressing the current translational barriers may lead to clinical success of NSC therapy and a first‐in‐class restorative therapy for stroke patients.

show abstract

Section: Fetal-derived Neural Stem Cellsmentioning

confidence: 99%

Neural stem cell therapy for stroke: A multimechanistic approach to restoring neurological function

2019

View full text Add to dashboard Cite

show abstract

“…Neural crest cells could be termed a dormant stem cell population in the adult, as they are pluripotent at first, but with migration they become restricted during development (Cheng et al 2012). Neural crest cells that form the vertebrate head skeleton migrate and interact with surrounding tissues to shape the skull.…”

Section: Introductionmentioning

confidence: 99%

Translational Research: Palatal-derived Ecto-mesenchymal Stem Cells from Human Palate: A New Hope for Alveolar Bone and Cranio-Facial Bone Reconstruction

Grimm¹,

Dannan²,

Giesenhagen³

et al. 2014

Int J Stem Cells

View full text Add to dashboard Cite

The management of facial defects has rapidly changed in the last decade. Functional and esthetic requirements have steadily increased along with the refinements of surgery. In the case of advanced atrophy or jaw defects, extensive horizontal and vertical bone augmentation is often unavoidable to enable patients to be fitted with implants. Loss of vertical alveolar bone height is the most common cause for a non primary stability of dental implants in adults. At present, there is no ideal therapeutic approach to cure loss of vertical alveolar bone height and achieve optimal pre-implantological bone regeneration before dental implant placement. Recently, it has been found that specific populations of stem cells and/or progenitor cells could be isolated from different dental resources, namely the dental follicle, the dental pulp and the periodontal ligament. Our research group has cultured palatal-derived stem cells (paldSCs) as dentospheres and further differentiated into various cells of the neuronal and osteogenic lineage, thereby demonstrating their stem cell state. In this publication will be shown whether paldSCs could be differentiated into the osteogenic lineage and, if so, whether these cells are able to regenerate alveolar bone tissue in vivo in an athymic rat model. Furthermore, using these data we have started a proof of principle clinical- and histological controlled study using stem cell-rich palatal tissues for improving the vertical alveolar bone augmentation in critical size defects. The initial results of the study demonstrate the feasibility of using stem cell-mediated tissue engineering to treat alveolar bone defects in humans.

show abstract

“…Experimental models of spinal cord trauma are largely employed [58–62]; however, analyses have failed to attempt the circumstances of related ischemia. This work performed a spinal cord injury photothrombotic ischemia using the Rose Bengal method, as first described by Watson et al [63], that has been widely employed in the cerebral ischemia studies.…”

Section: Discussionmentioning

confidence: 99%

Behavioral Improvement and Regulation of Molecules Related to Neuroplasticity in Ischemic Rat Spinal Cord Treated with PEDF

et al. 2014

View full text Add to dashboard Cite

Pigment epithelium derived factor (PEDF) exerts trophic actions to motoneurons and modulates nonneuronal restorative events, but its effects on neuroplasticity responses after spinal cord (SC) injury are unknown. Rats received a low thoracic SC photothrombotic ischemia and local injection of PEDF and were evaluated behaviorally six weeks later. PEDF actions were detailed in SC ventral horn (motor) in the levels of the lumbar central pattern generator (CPG), far from the injury site. Molecules related to neuroplasticity (MAP-2), those that are able to modulate such event, for instance, neurotrophic factors (NT-3, GDNF, BDNF, and FGF-2), chondroitin sulfate proteoglycans (CSPG), and those associated with angiogenesis and antiapoptosis (laminin and Bcl-2) and Eph (receptor)/ephrin system were evaluated at cellular or molecular levels. PEDF injection improved motor behavioral performance and increased MAP-2 levels and dendritic processes in the region of lumbar CPG. Treatment also elevated GDNF and decreased NT-3, laminin, and CSPG. Injury elevated EphA4 and ephrin-B1 levels, and PEDF treatment increased ephrin A2 and ephrins B1, B2, and B3. Eph receptors and ephrins were found in specific populations of neurons and astrocytes. PEDF treatment to SC injury triggered neuroplasticity in lumbar CPG and regulation of neurotrophic factors, extracellular matrix molecules, and ephrins.

show abstract

Functional assessment of the acute local and distal transplantation of human neural stem cells after spinal cord injury

Cited by 26 publications

References 13 publications

Neural stem cell therapy for stroke: A multimechanistic approach to restoring neurological function

Neural stem cell therapy for stroke: A multimechanistic approach to restoring neurological function

Translational Research: Palatal-derived Ecto-mesenchymal Stem Cells from Human Palate: A New Hope for Alveolar Bone and Cranio-Facial Bone Reconstruction

Behavioral Improvement and Regulation of Molecules Related to Neuroplasticity in Ischemic Rat Spinal Cord Treated with PEDF

Contact Info

Product

Resources

About